Afatinib (BIBW 2992): Irreversible ErbB Inhibitor for Cancer
2026-07-23
Afatinib (BIBW 2992) is an irreversible tyrosine kinase inhibitor that targets EGFR, HER2, and HER4 with high specificity. This compound is widely used in cancer biology research to dissect resistance mechanisms and optimize targeted therapy strategies. Its robust inhibition profile and solubility properties make it a preferred tool for advanced tumor modeling.
Mitoxantrone HCl Disrupts ERα via DBD-LBD Interface Targetin
2026-07-23
Wang et al. reveal a novel mechanism by which Mitoxantrone HCl targets the allosteric interface between the DNA-binding and ligand-binding domains of estrogen receptor alpha, promoting receptor degradation and disrupting signaling even in therapy-resistant mutants. These findings offer a new paradigm for targeting nuclear receptors beyond classical ligand competition and inform future breast cancer research strategies.
Mac-1 Deficiency Reduces Cardiac Remodeling via Macrophage M
2026-07-22
This study reveals that Mac-1 deficiency significantly ameliorates cardiac dysfunction and remodeling induced by pressure overload, primarily by inhibiting macrophage polarization and activation. The findings provide new mechanistic insight into heart failure progression and highlight Mac-1 as a potential therapeutic target.
Phenothiazines Boost Macrophage Antibacterial Activity via R
2026-07-22
The referenced study demonstrates that phenothiazines significantly enhance macrophage-mediated antibacterial defenses through the induction of autophagy and reactive oxygen species (ROS) accumulation. These findings highlight a promising host-directed therapeutic approach for combating intracellular bacterial infections and antibiotic resistance.
Catalpol (N1352): Protocol Guidance for Disease Model Resear
2026-07-21
Catalpol is a multi-target iridoid glycoside optimized for use in animal and cell-based models relevant to neuroprotection, osteoporosis, ischemic stroke, and liver fibrosis studies. This technical guide outlines practical dosing, solubility, and workflow recommendations for maximizing reproducibility. Use of Catalpol is best avoided in protocols where its pathway selectivity, solubility, or solution stability are not aligned with experimental requirements.
25-Hydroxycholesterol-AMPK Axis Shapes Tumor Macrophage Immu
2026-07-21
Xiao et al. uncover how 25-hydroxycholesterol (25HC) regulates immunosuppressive tumor-associated macrophages (TAMs) via a lysosomal AMPK activation pathway, influencing STAT6 signaling and tumor immune evasion. These insights highlight CH25H-25HC-AMPK as a pivotal immunometabolic checkpoint with therapeutic implications for cancer immunotherapy.
DeferoxamineB: Enhancing Cancer Research via Iron Chelation
2026-07-20
Deferoxamine (DeferoxamineB) empowers oncology labs to precisely modulate iron-driven cell death, enabling next-generation cancer models and metabolic interventions. This guide delivers advanced protocols, troubleshooting insights, and actionable advantages for integrating DeferoxamineB into ferroptosis and cuproptosis research.
C34 TLR4 Inhibitor: Precision Modulation of Gut and Immune I
2026-07-20
Explore how the C34 TLR4 inhibitor enables selective, high-fidelity modulation of inflammatory pathways in macrophages and enterocytes. This article goes beyond neuroinflammation, providing advanced insights for translational research in gut and systemic inflammatory diseases.
Medroxyprogesterone Acetate (MPA): Reliable Solutions for La
2026-07-19
This article addresses practical challenges in cell viability, proliferation, and reproductive model assays, illustrating how Medroxyprogesterone acetate (SKU B1510) delivers reproducibility and robust mechanistic data. Scenario-based guidance helps biomedical researchers optimize experimental design, interpretation, and product selection using validated protocols and literature-backed insights.
ML365 Attenuates POCD via NLRP3 Inflammasome Inhibition in M
2026-07-18
A recent study demonstrates that the selective TASK1 potassium channel inhibitor ML365 mitigates postoperative cognitive dysfunction (POCD) in aged mice by suppressing NLRP3 inflammasome activation in the hippocampus. This mechanistic insight connects ion channel pharmacology to neuroinflammation, informing neurophysiology research on age-related cognitive impairment.
Chloramphenicol for Translational Research: Mechanisms & Str
2026-07-17
Explore the mechanistic foundations and translational strategies for deploying chloramphenicol in molecular biology. This thought-leadership article connects recent epidemiological findings with practical guidance for robust plasmid selection and resistance studies, highlighting APExBIO's high-purity chloramphenicol as a trusted solution for researchers facing the challenges of multidrug resistance.
Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Resea
2026-07-17
Q-VD-OPh, a potent pan-caspase inhibitor from APExBIO, empowers researchers to precisely block caspase-mediated cell death across in vitro and in vivo models. Distinct for its cell permeability and high selectivity, Q-VD-OPh streamlines apoptosis research, enhances cell viability post-cryopreservation, and is validated in neurodegeneration studies.
MRTFA-KCNMB1 Axis: Regulating Cancer Cell Stiffness and Meta
2026-07-16
The reference study uncovers how the MRTFA-KCNMB1 axis modulates potassium channel activity to regulate cancer cell stiffness and metastatic potential. By demonstrating that pharmacological activation of BK channels increases stiffness and enhances immune-mediated cancer cell clearance, this work highlights new opportunities for targeting cell mechanics in metastatic disease.
Pam3CSK4 and TRPV1 Modulation: Next-Gen Models in Inflammati
2026-07-16
Explore how Pam3CSK4, a potent TLR1/2 agonist, enables advanced modeling of immune responses and inflammation. This article uniquely bridges molecular, cellular, and neuro-immune mechanisms to inform experimental design.
Technical Use of Angiotensin I/II (1-5) in RAS Research Work
2026-07-15
Angiotensin I/II (1-5) addresses the need for a defined Asp-Arg-Val-Tyr-Ile peptide fragment in controlled modeling of the renin-angiotensin system (RAS), particularly for studies of blood pressure regulation and aldosterone signaling. This product is not recommended for research outside cardiovascular or renal workflows due to its specific biochemical properties and solubility profile.
461 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page